WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
KR20200136508A
(en)
|
2013-04-16 |
2020-12-07 |
리제너론 파마슈티칼스 인코포레이티드 |
Targeted modification of rat genome
|
ES2883131T3
(en)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Methods for modifying T cells for immunotherapy using the RNA-guided CAS nuclease system
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
EP3988649A1
(en)
|
2013-09-18 |
2022-04-27 |
Kymab Limited |
Methods, cells and organisms
|
US10584358B2
(en)
|
2013-10-30 |
2020-03-10 |
North Carolina State University |
Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
|
WO2015070083A1
(en)
|
2013-11-07 |
2015-05-14 |
Editas Medicine,Inc. |
CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
|
CN105899232A
(en)
|
2013-11-13 |
2016-08-24 |
诺华股份有限公司 |
Mtor inhibitors for enhancing the immune response
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
CA2933433C
(en)
|
2013-12-11 |
2020-11-17 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
CA2932439A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute, Inc. |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
KR20230076867A
(en)
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Combination therapy with neoantigen vaccine
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
EP3105328B1
(en)
|
2014-02-11 |
2020-04-08 |
The Regents of the University of Colorado, a body corporate |
Crispr enabled multiplexed genome engineering
|
BR112016017806B1
(en)
|
2014-02-14 |
2023-05-02 |
Cellectis |
USE OF ENGINEERED T CELLS FOR IMMUNOTHERAPY AGAINST PATHOLOGICAL CELLS, AND EX VIVO METHOD FOR PREPARING THEM
|
JP2017512481A
(en)
|
2014-04-08 |
2017-05-25 |
ノースカロライナ ステート ユニバーシティーNorth Carolina State University |
Methods and compositions for RNA-dependent transcriptional repression using CRISPR-related genes
|
JP2017513472A
(en)
*
|
2014-04-11 |
2017-06-01 |
セレクティスCellectis |
Method for generating immune cells resistant to arginine and / or tryptophan depleted microenvironment
|
ES2962509T3
(en)
*
|
2014-04-14 |
2024-03-19 |
Maxcyte Inc |
Methods and compositions to modify genomic DNA
|
IL292512B1
(en)
*
|
2014-04-18 |
2024-03-01 |
Editas Medicine Inc |
Crispr–cas–related methods, compositions and components for cancer immunotherapy
|
JP7113618B2
(en)
|
2014-07-15 |
2022-08-05 |
ジュノー セラピューティクス インコーポレイテッド |
Engineered cells for adoptive cell therapy
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
WO2016033298A1
(en)
|
2014-08-28 |
2016-03-03 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
KR20230098910A
(en)
|
2014-10-31 |
2023-07-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Altering gene expression in modified t cells and uses thereof
|
EP3025719B1
(en)
|
2014-11-26 |
2018-09-26 |
Miltenyi Biotec GmbH |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
GB201421096D0
(en)
*
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
WO2016089433A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
LT3227339T
(en)
*
|
2014-12-05 |
2022-01-10 |
Memorial Sloan-Kettering Cancer Center |
Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
|
PT3227432T
(en)
|
2014-12-05 |
2023-12-06 |
Eureka Therapeutics Inc |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
SG10202008076RA
(en)
*
|
2014-12-05 |
2020-09-29 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
|
DK3226897T3
(en)
|
2014-12-05 |
2021-04-19 |
Memorial Sloan Kettering Cancer Center |
ANTIBODIES AFFECTING B-CELL MATURE ANTIGENASES AND METHODS OF USE
|
EP3227324A4
(en)
|
2014-12-05 |
2018-08-29 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting g-protein coupled receptor and methods of use
|
CA2969384A1
(en)
*
|
2014-12-17 |
2016-06-23 |
Cellectis |
Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
|
US20190054117A1
(en)
*
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
BR112017015453A2
(en)
*
|
2015-01-26 |
2018-01-23 |
Cellectis |
CD123-linked chimeric t-cell receptor knockout modified immune cells for the treatment of recurrent / refractory acute myeloid lymphoma or blastic neoplasia of plasmacitoid dendritic cells
|
SG11201706059SA
(en)
*
|
2015-01-30 |
2017-08-30 |
Univ California |
Protein delivery in primary hematopoietic cells
|
SI3253865T1
(en)
|
2015-02-06 |
2022-10-28 |
National University Of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
US20190024065A1
(en)
*
|
2015-02-06 |
2019-01-24 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
EP3262162A4
(en)
*
|
2015-02-23 |
2018-08-08 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
BR112017018224A2
(en)
|
2015-03-11 |
2018-04-17 |
Cellectis |
Methods for Allogeneic T Cell Manipulation to Increase Persistence and / or Implantation in Patients
|
EP3277805A1
(en)
*
|
2015-03-31 |
2018-02-07 |
Exeligen Scientific, Inc. |
Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism
|
KR20240038141A
(en)
|
2015-04-06 |
2024-03-22 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
CA2982759A1
(en)
*
|
2015-04-13 |
2016-10-20 |
Maxcyte, Inc. |
Methods and compositions for modifying genomic dna
|
KR102528825B1
(en)
|
2015-04-13 |
2023-05-08 |
화이자 인코포레이티드 |
Chimeric antigen receptors targeting b-cell maturation antigen
|
EP3284749A4
(en)
*
|
2015-04-13 |
2018-11-14 |
The University of Tokyo |
Set of polypeptides exhibiting nuclease activity or nickase activity with dependence on light or in presence of drug or suppressing or activating expression of target gene
|
BR112017024757A2
(en)
|
2015-05-18 |
2018-11-13 |
TCR2 Therapeutics Inc. |
compositions and methods for reprogramming tcr using fusion proteins
|
PE20180670A1
(en)
|
2015-05-20 |
2018-04-19 |
Broad Inst Inc |
SHARED NEOANTIGENS
|
CA2986359A1
(en)
|
2015-05-20 |
2016-11-24 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
EA201792663A1
(en)
|
2015-05-29 |
2018-04-30 |
Норт Каролина Стейт Юниверсити |
METHODS OF SCREENING BACTERIA, ARCHEAN, ALGAE AND YEAST WITH THE USE OF CRISPR NUCLEIC ACIDS
|
AU2016271147B2
(en)
*
|
2015-05-29 |
2022-09-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
KR20220158846A
(en)
|
2015-06-15 |
2022-12-01 |
노쓰 캐롤라이나 스테이트 유니버시티 |
Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
|
CA2989831A1
(en)
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for genomic editing
|
CA2989858A1
(en)
*
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
WO2016205688A2
(en)
*
|
2015-06-18 |
2016-12-22 |
Bowles Robert D |
Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
|
WO2017004261A1
(en)
*
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
MA42895A
(en)
*
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
US20170020922A1
(en)
*
|
2015-07-16 |
2017-01-26 |
Batu Biologics Inc. |
Gene editing for immunological destruction of neoplasia
|
EP3325018A4
(en)
|
2015-07-22 |
2019-04-24 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
WO2017023801A1
(en)
*
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
JP2018522907A
(en)
*
|
2015-08-11 |
2018-08-16 |
セレクティスCellectis |
Cells for immunotherapy engineered to target the CD38 antigen and to inactivate the CD38 gene
|
BR112018003625A2
(en)
|
2015-08-25 |
2018-09-25 |
Univ Duke |
genomic engineering specificity enhancement compositions and methods using rna-guided endonucleases
|
US11890301B2
(en)
*
|
2015-08-28 |
2024-02-06 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
WO2017049266A2
(en)
*
|
2015-09-18 |
2017-03-23 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
|
EP3349797A4
(en)
*
|
2015-09-18 |
2019-06-12 |
The General Hospital Corporation Dba Massachusetts General Hospital |
Localized delivery of anti-fugetactic agent for treatment of cancer
|
US11286480B2
(en)
|
2015-09-28 |
2022-03-29 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
WO2017059241A1
(en)
*
|
2015-10-02 |
2017-04-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
EP3940070A1
(en)
|
2015-10-05 |
2022-01-19 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
EP4108255A1
(en)
*
|
2015-10-05 |
2022-12-28 |
Precision Biosciences, Inc. |
Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP3362571A4
(en)
|
2015-10-13 |
2019-07-10 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
WO2017066588A2
(en)
*
|
2015-10-16 |
2017-04-20 |
Temple University - Of The Commonwealth System Of Higher Education |
Methods and compositions utilizing cpf1 for rna-guided gene editing
|
AU2016337525B2
(en)
|
2015-10-16 |
2022-01-20 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for inhibition of lineage specific antigens
|
WO2017070429A1
(en)
*
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
JP7109784B2
(en)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Evolved Cas9 protein for gene editing
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
EP3370741A4
(en)
*
|
2015-11-04 |
2019-04-24 |
The Trustees of The University of Pennsylvania |
Methods and compositions for gene editing in hematopoietic stem cells
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
EP3384027A1
(en)
*
|
2015-12-04 |
2018-10-10 |
Novartis AG |
Compositions and methods for immunooncology
|
MY197441A
(en)
|
2015-12-04 |
2023-06-19 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting fc receptor-like 5 and method of use
|
AU2016369490C1
(en)
*
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
CN106967685B
(en)
*
|
2016-01-13 |
2020-06-02 |
北京马力喏生物科技有限公司 |
Transgenic lymphocytes co-expressing anti-EGFRvIII chimeric antigen receptor and immune checkpoint inhibitory molecules and uses thereof
|
CN106967681B
(en)
*
|
2016-01-13 |
2020-06-05 |
北京马力喏生物科技有限公司 |
Therapeutic composition for treating glioblastoma
|
UA125252C2
(en)
|
2016-01-21 |
2022-02-09 |
Пфайзер Інк. |
Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
|
WO2017152015A1
(en)
*
|
2016-03-04 |
2017-09-08 |
Editas Medicine, Inc. |
Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
CA3020330A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
KR20240000616A
(en)
|
2016-04-15 |
2024-01-02 |
메모리얼 슬로안 케터링 캔서 센터 |
Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
|
EP3429633B1
(en)
*
|
2016-04-15 |
2021-02-24 |
Cellectis |
A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
CN107304434A
(en)
*
|
2016-04-25 |
2017-10-31 |
上海宇玫博生物科技有限公司 |
A kind of difunctional novel carriers of immune cell therapy
|
CA3022611A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
WO2017223538A1
(en)
|
2016-06-24 |
2017-12-28 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods for generating barcoded combinatorial libraries
|
AU2017291851B2
(en)
*
|
2016-07-06 |
2022-10-13 |
Cellectis |
Sequential gene editing in primary immune cells
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
EP3494215A1
(en)
|
2016-08-03 |
2019-06-12 |
President and Fellows of Harvard College |
Adenosine nucleobase editors and uses thereof
|
JP7201153B2
(en)
|
2016-08-09 |
2023-01-10 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Programmable CAS9-recombinase fusion protein and uses thereof
|
EP3497221A4
(en)
*
|
2016-08-10 |
2020-02-05 |
Duke University |
Compositions, systems and methods for programming immune cell function through targeted gene regulation
|
CN109844118A
(en)
|
2016-08-12 |
2019-06-04 |
株式会社图尔金 |
Immune-regulating factor through manipulating and the immunity thus changed
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
US11096998B2
(en)
|
2016-09-14 |
2021-08-24 |
Janssen Biotech, Inc. |
Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof
|
KR20190062505A
(en)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
HPV-specific binding molecules
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
MX2019003899A
(en)
|
2016-10-07 |
2019-08-14 |
Tcr2 Therapeutics Inc |
Compositions and methods for t-cell receptors reprogramming using fusion proteins.
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
CN110520530A
(en)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
Tumor infiltrating lymphocyte and treatment method
|
WO2018073394A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
US20230138915A1
(en)
*
|
2016-10-19 |
2023-05-04 |
Cellectis |
TAL- effector nuclease (TALEN) -MODIFIED ALLOGENIC CELLS SUITABLE FOR THERAPY
|
WO2018073391A1
(en)
*
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
US11873511B2
(en)
|
2016-10-19 |
2024-01-16 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
EP3532105A4
(en)
|
2016-10-31 |
2020-05-27 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogennous foxp3 gene
|
DK3321280T3
(en)
|
2016-11-10 |
2021-02-22 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
IMMUNE MODULATORS FOR REDUCING IMMUNE RESISTANCE IN A MELANOME AND OTHER PROLIFERATIVE DISEASES
|
WO2018087276A1
(en)
|
2016-11-10 |
2018-05-17 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Or10h1 modulators and uses thereof
|
JP7291396B2
(en)
|
2016-11-22 |
2023-06-15 |
ティーシーアール2 セラピューティクス インク. |
Compositions and methods for TCR reprogramming using fusion proteins
|
CN110268049B
(en)
|
2016-11-22 |
2024-06-14 |
新加坡国立大学 |
CD7 expression blockers and chimeric antigen receptors for T cell malignancy immunotherapy
|
CA3044355A1
(en)
|
2016-11-23 |
2018-05-31 |
Novartis Ag |
Methods of enhancing immune response with everolimus, dactolisib or both
|
EP3559214A1
(en)
*
|
2016-12-21 |
2019-10-30 |
UCL Business PLC |
Therapeutic cells
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
CN107760680B
(en)
*
|
2016-12-28 |
2020-09-22 |
北京微旋基因技术有限公司 |
sgRNA of specific targeting TIM-3 gene and method for specifically knocking out TIM-3 gene
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
EP3573657A4
(en)
*
|
2017-01-29 |
2021-04-14 |
Zequn Tang |
Methods of immune modulation against foreign and/or auto antigens
|
TW201839136A
(en)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
Compositions and methods for the treatment of hemoglobinopathies
|
WO2018148224A1
(en)
|
2017-02-07 |
2018-08-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
US11845803B2
(en)
|
2017-02-17 |
2023-12-19 |
Fred Hutchinson Cancer Center |
Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
|
KR20190141657A
(en)
|
2017-02-28 |
2019-12-24 |
보르 바이오파마, 인크. |
Compositions and Methods for Inhibition of Lineage Specific Proteins
|
US11850262B2
(en)
|
2017-02-28 |
2023-12-26 |
Purdue Research Foundation |
Compositions and methods for CAR T cell therapy
|
KR20190123328A
(en)
*
|
2017-03-09 |
2019-10-31 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Cancer vaccine
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
EP3601561A2
(en)
*
|
2017-03-22 |
2020-02-05 |
Novartis AG |
Compositions and methods for immunooncology
|
IL269458B2
(en)
|
2017-03-23 |
2024-02-01 |
Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
KR20200015467A
(en)
|
2017-03-31 |
2020-02-12 |
셀렉티스 |
Universal Anti-CD22 Chimeric Antigen Receptor Engineered Immune Cells
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
DK3391907T3
(en)
|
2017-04-20 |
2020-03-09 |
Iomx Therapeutics Ag |
INTRACELLULAR KINASE SIK3, ASSOCIATED WITH RESISTANCE TO ANTITUMOR IMMUNE RESPONSES, AND APPLICATIONS THEREOF
|
JP7235391B2
(en)
*
|
2017-05-08 |
2023-03-08 |
ツールゲン インコーポレイテッド |
artificially engineered immune cells
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
KR20200005596A
(en)
|
2017-05-12 |
2020-01-15 |
크리스퍼 테라퓨틱스 아게 |
Materials and methods for engineering cells, and their use in immuno-oncology
|
EP3630980B1
(en)
|
2017-06-01 |
2023-11-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cell preparation and uses thereof
|
SG10202108528QA
(en)
|
2017-06-02 |
2021-09-29 |
Pfizer |
Chimeric antigen receptors targeting flt3
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
EP3638317A4
(en)
|
2017-06-15 |
2021-03-17 |
The Regents of The University of California |
Targeted non-viral dna insertions
|
AU2018288863A1
(en)
*
|
2017-06-22 |
2020-01-30 |
Board Of Regents, The University Of Texas System |
Methods for producing regulatory immune cells and uses thereof
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
JP2020530307A
(en)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス,インコーポレーテッド |
Adeno-associated virus vector for gene therapy
|
US11235004B2
(en)
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
WO2019002633A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
EP3645038A1
(en)
|
2017-06-30 |
2020-05-06 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
MA49652A
(en)
|
2017-07-17 |
2020-05-27 |
Janssen Biotech Inc |
ANTIGEN-BINDING REGIONS DIRECTED TO FIELDS OF FIBRONECTIN TYPE III AND THEIR METHODS OF USE
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
WO2019052577A1
(en)
*
|
2017-09-18 |
2019-03-21 |
博雅辑因(北京)生物科技有限公司 |
Gene editing t cell and use thereof
|
US20200230221A1
(en)
|
2017-09-19 |
2020-07-23 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
US11618896B2
(en)
|
2017-09-21 |
2023-04-04 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
KR20200104284A
(en)
|
2017-10-03 |
2020-09-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
HPV-specific binding molecule
|
CN111757937A
(en)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
Use of adenosine base editor
|
EP3684919A1
(en)
*
|
2017-10-19 |
2020-07-29 |
Cellectis |
Targeted gene integration of nk inhibitors genes for improved immune cells therapy
|
US20210071139A1
(en)
*
|
2017-10-27 |
2021-03-11 |
The Trustees Of The University Of Pennsylvania |
Identifying Epigenetic And Transcriptional Targets To Prevent And Reverse T Cell Exhaustion
|
IL274179B2
(en)
|
2017-10-27 |
2024-02-01 |
Univ California |
Targeted replacement of endogenous t cell receptors
|
MA50860A
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
CHEMERICAL RECEPTERS OF ANTIGEN AGAINST B-CELL MATURATION ANTIGEN AND CODING POLYNUCLEOTIDES
|
WO2019089969A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
AU2018359532B2
(en)
|
2017-11-01 |
2024-03-28 |
Allogene Therapeutics, Inc. |
Modified caspase-9 polypeptides and methods of use thereof
|
CN109750035B
(en)
*
|
2017-11-02 |
2020-06-05 |
上海邦耀生物科技有限公司 |
sgRNA for targeting and guiding Cas9 protein to efficiently cleave TCR and B2M gene locus
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
US11738047B2
(en)
|
2017-12-12 |
2023-08-29 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
|
US11793867B2
(en)
|
2017-12-18 |
2023-10-24 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
EP3508499A1
(en)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
|
WO2019138354A1
(en)
|
2018-01-12 |
2019-07-18 |
Curocell Inc. |
Enhanced immune cells using dual shrna and composition including the same
|
CN112292138A
(en)
|
2018-01-22 |
2021-01-29 |
西雅图儿童医院(Dba西雅图儿童研究所) |
Methods of use of CAR T cells
|
PT110526B
(en)
|
2018-01-26 |
2021-02-04 |
Univ Nova De Lisboa |
ANTIBODY, FUNCTIONAL FRAGMENT OR PROBE OF THE SAME AGAINST TUMORAL ANTIGENS
|
PE20210708A1
(en)
|
2018-02-01 |
2021-04-16 |
Pfizer |
ANTIBODIES SPECIFIC TO CD70 AND THEIR USES
|
CN112020518A
(en)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
Chimeric antigen receptor targeting CD70
|
WO2019166946A1
(en)
|
2018-02-28 |
2019-09-06 |
Pfizer Inc. |
Il-15 variants and uses thereof
|
US11447769B2
(en)
|
2018-03-27 |
2022-09-20 |
The Trustees Of The University Of Pennsylvania |
Modified immune cells having enhanced function and methods for screening for same
|
MX2020010459A
(en)
|
2018-04-05 |
2021-01-20 |
Juno Therapeutics Inc |
Methods of producing cells expressing a recombinant receptor and related compositions.
|
CA3095027A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
JP2021520211A
(en)
|
2018-04-05 |
2021-08-19 |
ジュノー セラピューティクス インコーポレイテッド |
T cells expressing recombinant receptors, related polynucleotides, and methods
|
IL304025A
(en)
|
2018-04-12 |
2023-08-01 |
Prec Biosciences Inc |
Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
CA3091688A1
(en)
|
2018-04-27 |
2019-10-31 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Expression of foxp3 in edited cd34+ cells
|
AU2019265539A1
(en)
*
|
2018-05-07 |
2020-11-26 |
The Regents Of The University Of California |
Compositions and methods for modifying regulatory T cells
|
EP3790629A1
(en)
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Methods and compositions for treating cancer
|
GB2589246A
(en)
|
2018-05-16 |
2021-05-26 |
Synthego Corp |
Methods and systems for guide RNA design and use
|
CA3100247A1
(en)
*
|
2018-05-17 |
2019-11-21 |
Regents Of The Univesity Of Minnesota |
Drug-resistant immune cells and methods of use thereof
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
WO2019237398A1
(en)
*
|
2018-06-16 |
2019-12-19 |
深圳市博奥康生物科技有限公司 |
Grna targeting sequence of specific target human cd272 gene and application thereof
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
US20210177832A1
(en)
|
2018-08-20 |
2021-06-17 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
MX2021002415A
(en)
|
2018-08-28 |
2021-09-21 |
Vor Biopharma Inc |
Genetically engineered hematopoietic stem cells and uses thereof.
|
US11845958B2
(en)
*
|
2018-09-05 |
2023-12-19 |
Wisconsin Alumni Research Foundation |
Genetically modified genes and cells, and methods of using same for silencing virus gene expression
|
AU2019341365A1
(en)
*
|
2018-09-21 |
2021-05-27 |
Crage Medical Co., Limited |
Method for gene editing of cell on the basis of CRISPR/Cas system
|
SG11202100935TA
(en)
|
2018-09-28 |
2021-02-25 |
Massachusetts Inst Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
EP3867379A1
(en)
*
|
2018-10-16 |
2021-08-25 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
WO2020109953A1
(en)
|
2018-11-30 |
2020-06-04 |
Janssen Biotech, Inc. |
Gamma delta t cells and uses thereof
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CN109722437B
(en)
*
|
2018-12-29 |
2020-01-07 |
广州百暨基因科技有限公司 |
Universal CAR-T cell and preparation method and application thereof
|
CN109652378B
(en)
*
|
2018-12-29 |
2020-04-24 |
广州百暨基因科技有限公司 |
Function-enhanced universal CAR-T cell and preparation method and application thereof
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
SG11202109882VA
(en)
|
2019-03-19 |
2021-10-28 |
Broad Inst Inc |
Methods and compositions for editing nucleotide sequences
|
JP2022524221A
(en)
*
|
2019-03-22 |
2022-04-28 |
スポットライト セラピューティクス |
Target-directed active gene editor and usage
|
EP3962535A1
(en)
|
2019-04-30 |
2022-03-09 |
CRISPR Therapeutics AG |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
BR112021021075A2
(en)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
WO2020223571A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
EP3736330A1
(en)
|
2019-05-08 |
2020-11-11 |
European Molecular Biology Laboratory |
Modified adeno-associated virus (aav) particles for gene therapy
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
WO2020263399A1
(en)
|
2019-06-26 |
2020-12-30 |
Massachusetts Institute Of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
EP3994171A1
(en)
|
2019-07-05 |
2022-05-11 |
iOmx Therapeutics AG |
Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021041486A1
(en)
|
2019-08-27 |
2021-03-04 |
Janssen Biotech, Inc. |
Chimeric antigen receptor system and uses thereof
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
MX2022010824A
(en)
|
2020-03-03 |
2022-11-30 |
Janssen Biotech Inc |
ê©Î´ T CELLS AND USES THEREOF.
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
WO2021188384A1
(en)
*
|
2020-03-14 |
2021-09-23 |
Berkeley Lights, Inc. |
Methods of amplifying paired transcript sequences from single cells
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
JP2023525304A
(en)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート,インコーポレーテッド |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
EP3910331A1
(en)
|
2020-05-15 |
2021-11-17 |
iOmx Therapeutics AG |
Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereof
|
CN116234558A
(en)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
Engineered T cells conditionally expressing recombinant receptors, related polynucleotides and methods
|
EP4175668A1
(en)
|
2020-07-06 |
2023-05-10 |
iOmx Therapeutics AG |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
CA3185197A1
(en)
|
2020-07-21 |
2022-01-27 |
Allogene Therapeutics, Inc. |
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
|
EP3957720A1
(en)
|
2020-08-21 |
2022-02-23 |
Charité - Universitätsmedizin Berlin |
Immunosuppressant-resistant t-cells for adoptive immunotherapy
|
CA3182371A1
(en)
*
|
2020-08-14 |
2022-02-17 |
Charite - Universitatsmedizin Berlin |
Immunosuppressant-resistant t-cells for adoptive immunotherapy
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
WO2022101363A1
(en)
|
2020-11-11 |
2022-05-19 |
European Molecular Biology Laboratory |
Modified viral particles for gene therapy
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
WO2022132756A1
(en)
*
|
2020-12-14 |
2022-06-23 |
Emendobio Inc. |
Biallelic knockout of trac
|
EP4039808A1
(en)
*
|
2021-02-08 |
2022-08-10 |
Ospedale San Raffaele S.r.l. |
Guide rnas and uses thereof
|
US20240108654A1
(en)
|
2021-03-03 |
2024-04-04 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
WO2022215978A1
(en)
*
|
2021-04-05 |
2022-10-13 |
주식회사 셀렌진 |
Guide rna complementary to pdcd-1 gene and use thereof
|
EP4377460A1
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
EP4377459A2
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
WO2023039586A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023167575A1
(en)
*
|
2022-03-04 |
2023-09-07 |
주식회사 툴젠 |
Low immunogenic stem cells, low immunogenic cells differentiated or derived from stem cells, and production method therefor
|
WO2023224715A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
US20240067969A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|